Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

BACKGROUND: Patients with chronic lymphocytic leukaemia (CLL) with TP53 aberrations respond poorly to first-line chemoimmunotherapy resulting in early relapse and short survival. We investigated the safety and activity of ibrutinib in previously untreated and relapsed or refractory CLL with TP53 abe...

全面介紹

Na minha lista:
書目詳細資料
發表在:Lancet Oncol
Main Authors: Farooqui, Mohammed Z H, Valdez, Janet, Martyr, Sabrina, Aue, Georg, Saba, Nakhle, Niemann, Carsten U, Herman, Sarah E M, Tian, Xin, Marti, Gerald, Soto, Susan, Hughes, Thomas E, Jones, Jade, Lipsky, Andrew, Pittaluga, Stefania, Stetler-Stevenson, Maryalice, Yuan, Constance, Lee, Yuh Shan, Pedersen, Lone B, Geisler, Christian H, Calvo, Katherine R, Arthur, Diane C, Maric, Irina, Childs, Richard, Young, Neal S, Wiestner, Adrian
格式: Artigo
語言:Inglês
出版: 2014
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4342187/
https://ncbi.nlm.nih.gov/pubmed/25555420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)71182-9
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍